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Acute rheumatic fever (ARF) and rheumatic heart 
disease (RHD) are still a major burden in developing 
countries. The World Heart Federation has made the 
elimination of ARF and control of RHD one of the six 
main goals in its strategic plan through 2015.[1] 
Primary prevention of ARF and RHD depends on preventing the 
initial attacks of ARF by means of short-term oral or intramuscular 
(IM) penicillin treatment of patients presenting with acute sore 
throat (pharyngitis) caused by an infection with the group A 
Streptococcus pyogenes. Yet primary prevention has not been widely 
adopted in developing countries owing to health system barriers 
and a concern about its cost-effectiveness.[2] Barriers include poor 
access to primary care, the expense of microbiological diagnosis, 
shortage of skilled staff and poor public awareness about diagnosis 
and prompt treatment of suspected streptococcal pharyngitis. 
A public health strategy of primary prevention in a country like 
South Africa (SA) should limit costly diagnostic testing, minimise 
unnecessary antibiotic treatment, and be sensitive enough to 
minimise missed diagnoses. 
The presentation of children with suspected streptococcal 
pharyngitis to primary care clinics in a RHD study area in Cape Town 
provided us with the opportunity to undertake a cost-effectiveness 
analysis of seven strategies for the primary prevention of ARF and 
RHD in children with pharyngitis in urban SA.[3] We included five 
single-stage strategies and two two-stage screening strategies in our 
decision analysis model. Some of these strategies included a simple 
modified World Health Organization (WHO) clinical decision rule 
(CDR) that uses a symptomatic score (0 - 3) based on the presence 
of enlarged cervical nodes, absence of rhinitis, and absence of rash. [4] 
The seven categories were thus: (i) empirical treatment with IM 
penicillin (Treat All); (ii) treatment based on a positive throat culture 
(Culture All); (iii) treatment based on a symptomatic score of 2 using a 
modified WHO CDR (CDR 2+); (iv) treatment based on a CDR score 
of ≥3 (CDR 3+); (v) treating those with a CDR score of ≥2, culturing 
those with CDR scores <2 and then treating positive cultures (CDR2+, 
Culture CDR negatives); (vi) treating those with a CDR ≥3, culturing 
those with CDR scores <3 and treating positive cultures (CDR3+, 
Culture CDR negatives); and (vii) observation only (Treat None). The 
two-stage strategies were included to improve the sensitivity of the 
screening process and to decrease the costs of culture of throat swabs. 
Rapid streptococcus antigen tests are not currently used in public 
sector primary care settings and thus were not evaluated. National 
guidelines on primary prevention encourage IM penicillin because of 
better adherence and greater effectiveness than oral regimens.[5] 
Table 1 shows the analysis of the costs (in US$ at 2010 exchange 
rates), effects in quality-adjusted life years (QALYs) gained and 
incremental cost-effectiveness ratios (ICERs) for the seven strategies, 
in order of increasing cost.
From this analysis it is apparent that:
• Treating all children presenting with suspected pharyngitis with 
IM penicillin is marginally the least costly strategy (US$11.19 or 
R82 per case).
• There is little difference in the effectiveness of the strategies.
• Treating only children with ≥2 symptoms (CDR2+) on a 3-symptom 
score CDR is the most cost-effective strategy (US$136 or R994 per 
QALY gained compared with treating all cases).
• Culturing all children is the most costly strategy. At US$127 600 
or R932  437 per QALY gained, it far exceeds the 2010 cost-
effectiveness threshold for SA of US$30 000 per QALY used by the 
WHO Commission on Macroeconomics and Health.
A group A Streptococcus prevalence of 15%, an ARF attack rate of 
0.3%, and a risk of penicillin-induced anaphylaxis of 1/10 000 were 
deemed appropriate for this setting. In sensitivity analysis testing, 
only a decrease in group A Streptococcus prevalence below 12.9%, an 
increase in the ARF attack rate above 1%, and an increase in the risk 
of penicillin-induced anaphylaxis above 3.4/10 000 cases, altered the 
model conclusions. 
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Primary prevention of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) in children depends on prompt and effective 
diagnosis and treatment of pharyngitis at the primary level of care. Cost-effectiveness modeling shows that the most cost-effective strategy 
for primary prevention in South Africa (SA) is to use a simple symptomatic clinical decision rule (CDR) to diagnose pharyngitis in children 
presenting at the primary level of care and then to treat them with a single dose of intramuscular penicillin. Treat All and CDR2+ strategies 
are affordable and simple and miss few cases of streptococcal pharyngitis at the primary level of care. The CDR2+ strategy is the most 
cost-effective for primary prevention of ARF and RHD in urban SA and should complement primordial and secondary prevention efforts.
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Both the Treat All and CDR2+ strategies are affordable and simple and 
miss few cases of streptococcal pharyngitis at the primary level of care. 
The CDR2+ strategy is the most cost-effective in settings with a similar 
group A Streptococcus prevalence and ARF attack rate in the Cape Town 
study area. A strategy for primary prevention of ARF and RHD in urban 
SA should be adopted to complement strategies to improve primordial 
prevention (better housing and hygiene) and secondary prevention 
(regular penicillin for those with a history of ARF). 
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Table 1. Costs, effects and incremental cost-effectiveness of primary prevention strategies
Strategy Cost (US$) Effect (QALY) ICER (US$/QALY)
Treat all 11.19 22.939936
CDR 2+ 11.20 22.940002 136
CDR 3+ 13.00 22.939961 Dominated*
Treat none 14.39 22.939899 Dominated*
CDR 2+, Culture CDR negatives 16.42 22.940017 Dominated†
CDR 3+, Culture CDR negatives 23.89 22.940101 Dominated†
Culture All 27.21 22.940128 127 600
CDR = clinical decision rule; US$ = United States dollars; QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio.
* Dominated strategies are those which are less effective than a less costly strategy. †Dominated strategies which have higher ICERs than a more effective strategy and which are eliminated by a blend of 2 other strategies (‘extended dominance’)
